RNC Capital Management LLC Acquires 1,237 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• RNC Capital Management LLC increased its stake in Thermo Fisher Scientific Inc. by 12.6% during the 1st quarter, now owning a total of 11,017 shares valued at approximately $5.48 million.
• Though most analysts have rated the stock as a "Moderate Buy," recent ratings have varied, with Royal Bank of Canada setting a target price at $561.00 and Wall Street Zen downgrading their rating from "buy" to "hold."
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, with a record date of September 15th, reflecting a 0.3% yield.

RNC Capital Management LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,017 shares of the medical research company's stock after acquiring an additional 1,237 shares during the quarter. RNC Capital Management LLC's holdings in Thermo Fisher Scientific were worth $5,482,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. GAMMA Investing LLC lifted its stake in Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares in the last quarter. Nuveen LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $532,360,000. Sarasin & Partners LLP bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $242,991,000. Two Sigma Advisers LP boosted its position in Thermo Fisher Scientific by 81.6% during the 4th quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock valued at $485,479,000 after buying an additional 419,200 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at $195,049,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 over the last three months. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of several analyst reports. Raymond James Financial reissued an "outperform" rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. UBS Group raised their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, HSBC reaffirmed a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $589.38.

Thermo Fisher Scientific Stock Down 1.1%

NYSE:TMO traded down $5.38 on Wednesday, reaching $477.03. 1,442,085 shares of the stock traded hands, compared to its average volume of 1,608,466. The company has a market capitalization of $180.13 billion, a price-to-earnings ratio of 27.59, a PEG ratio of 2.58 and a beta of 0.75. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The company's fifty day simple moving average is $464.58 and its 200 day simple moving average is $452.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.